ethylmethylhydroxypyridine-succinate and Coronary-Artery-Disease

ethylmethylhydroxypyridine-succinate has been researched along with Coronary-Artery-Disease* in 2 studies

Trials

1 trial(s) available for ethylmethylhydroxypyridine-succinate and Coronary-Artery-Disease

Article	Year
[The effects of mexicor on thrombocyte aggregation, blood viscosity, hemodynamics, and the clinical course of coronary artery disease]. Klinicheskaia meditsina, 2006, Volume: 84, Issue:10 The authors analyze their experience in the application of mexicor, a Russian cytoprotector, in 50patients with chronic coronary artery disease (CAD) and 51 patients with acute coronary syndrome. In additional to cytoprotective action, the use of mexidor in complex therapy of CAD lowers the functional activity of thrombocytes, eliminates high blood viscosity syndrome, and lowers low density lipoprotein cholesterol level. These favorable changes in hemorheological parameters improves myocardial perfusion, lowers the strength and frequency of coronary pain attacks, retards postinfarction left ventricular remodeling, and increases the quality of life of patients with various CAD forms. Topics: Acute Disease; Adult; Angina, Unstable; Blood Platelets; Blood Viscosity; Chronic Disease; Coronary Artery Disease; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyridines	2006

Article

Year

[The effects of mexicor on thrombocyte aggregation, blood viscosity, hemodynamics, and the clinical course of coronary artery disease].

Klinicheskaia meditsina, 2006, Volume: 84, Issue:10

The authors analyze their experience in the application of mexicor, a Russian cytoprotector, in 50patients with chronic coronary artery disease (CAD) and 51 patients with acute coronary syndrome. In additional to cytoprotective action, the use of mexidor in complex therapy of CAD lowers the functional activity of thrombocytes, eliminates high blood viscosity syndrome, and lowers low density lipoprotein cholesterol level. These favorable changes in hemorheological parameters improves myocardial perfusion, lowers the strength and frequency of coronary pain attacks, retards postinfarction left ventricular remodeling, and increases the quality of life of patients with various CAD forms.

Topics: Acute Disease; Adult; Angina, Unstable; Blood Platelets; Blood Viscosity; Chronic Disease; Coronary Artery Disease; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyridines

2006

Other Studies

1 other study(ies) available for ethylmethylhydroxypyridine-succinate and Coronary-Artery-Disease

Article	Year
[First experience in using cardiocytoprotector mexicor in operations of myocardial revascularization under conditions of extracorporeal circulation]. Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery, 2009, Volume: 15, Issue:1 We examined a total of forty-four patients diagnosed with coronary artery disease who were subjected to coronary artery bypass graft surgery under conditions of extracorporeal circula tion. In the examined group (15 patients) during anaesthesia and perfusion, we additionally administered the cardiocytoprotector mexicor at a total dose of 1,500 mg. It was revealed that administering mexicor in a complex of anaesthesiological-and-resuscitation support considerably increased the indices of myocardial contractility and oxygen-transporting function of blood in the postperfusion period, also decreasing both the amount and duration of inotropic stimulation, and favourably contributing to early recovery and restoration of spontaneous respiration in the immediate postoperative period. Topics: Coronary Artery Bypass; Coronary Artery Disease; Dose-Response Relationship, Drug; Extracorporeal Circulation; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Intraoperative Period; Male; Middle Aged; Myocardial Contraction; Pyridines; Treatment Outcome	2009

Article

Year

[First experience in using cardiocytoprotector mexicor in operations of myocardial revascularization under conditions of extracorporeal circulation].

Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery, 2009, Volume: 15, Issue:1

We examined a total of forty-four patients diagnosed with coronary artery disease who were subjected to coronary artery bypass graft surgery under conditions of extracorporeal circula tion. In the examined group (15 patients) during anaesthesia and perfusion, we additionally administered the cardiocytoprotector mexicor at a total dose of 1,500 mg. It was revealed that administering mexicor in a complex of anaesthesiological-and-resuscitation support considerably increased the indices of myocardial contractility and oxygen-transporting function of blood in the postperfusion period, also decreasing both the amount and duration of inotropic stimulation, and favourably contributing to early recovery and restoration of spontaneous respiration in the immediate postoperative period.

Topics: Coronary Artery Bypass; Coronary Artery Disease; Dose-Response Relationship, Drug; Extracorporeal Circulation; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Intraoperative Period; Male; Middle Aged; Myocardial Contraction; Pyridines; Treatment Outcome

2009